Samsung Group has expanded its position in the biosimilar filed, establishing 13 pipelines
Samsung Group has been accelerated in expansion of its biosimilar business.
Samsung has currently shown rapid movements in the biopharmaceutical industry market through ‘Samsung Bioepis,’ a biopharmaceutical development and sales company, and ‘Samsung Biologics,’ a biopharmaceutical product proc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
